Flt3l
Showing 26 - 50 of >10,000
Non Small Cell Lung Cancer, Lung Cancer Trial in Bronx (drug, biological, radiation)
Recruiting
- Non Small Cell Lung Cancer
- Lung Cancer
- FLT3 Ligand (CDX-301)
- +2 more
-
Bronx, New YorkAlbert Einstein College of Medicine
Jul 18, 2022
Acute Myeloid Leukemia Trial in Miami (CPX-351, Midostaurin, Busulfan)
Recruiting
- Acute Myeloid Leukemia
- CPX-351
- +5 more
-
Miami, FloridaMiami Cancer Institute at Baptist Health of South Florida
Jul 27, 2022
Acute Myeloid Leukemia (AML) Trial in United States (Gilteritinib, Ivosidenib, Enasidenib)
Not yet recruiting
- Acute Myeloid Leukemia (AML)
- Gilteritinib
- +2 more
-
Basking Ridge, New Jersey
- +6 more
Mar 3, 2023
Metastatic Triple Negative Breast Cancer Trial in Dallas (PLD Chemotherapy, CDX-1140, CDX-301)
Recruiting
- Metastatic Triple Negative Breast Cancer
- PLD Chemotherapy
- +2 more
-
Dallas, TexasUT Southwestern Medical Center
Jun 23, 2022
Graft Vs Host Disease Trial in Chapel Hill (Fluorothymidine (FLT))
Active, not recruiting
- Graft Vs Host Disease
- Fluorothymidine (FLT)
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center
Mar 21, 2022
FMS-Like Tyrosine Kinase 3-mutated Acute Myeloid Leukemia Trial (midostaurin)
Available
- FMS-Like Tyrosine Kinase 3-mutated Acute Myeloid Leukemia
- (no location specified)
Oct 18, 2022
Xospata in Relapsed or Refractory Acute Myeloid Leukemia With
Recruiting
- Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
- Gilteritinib Exposure
-
Goyang-si, Gyeonggi-do, Korea, Republic of
- +4 more
Aug 18, 2022
Acute Myeloid Leukemia Trial in Spain (Quizartinib, Placebo oral tablet, Cytarabine)
Active, not recruiting
- Acute Myeloid Leukemia
- Quizartinib
- +3 more
-
Santiago De Compostela, A Coruña, Spain
- +44 more
Jan 20, 2022
Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in United States (Lanraplenib,
Recruiting
- Acute Myeloid Leukemia
- +2 more
-
Los Angeles, California
- +3 more
Aug 4, 2022
Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia Trial in Columbus (Azacitidine,
Recruiting
- Acute Myeloid Leukemia
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Jan 4, 2022
Ewing Sarcoma Trial in United States (drug, diagnostic test, other)
Recruiting
- Ewing Sarcoma
- Trabectedin 1 MG [Yondelis]
- +3 more
-
Los Angeles, California
- +5 more
Aug 15, 2022
Advanced Cancer Trial in Houston (FLT-PET)
Completed
- Advanced Cancer
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jan 3, 2022
Relapsed/Refractory Acute Myeloid Leukemia Trial in Duarte, Palo Alto, Houston (AMG 553)
Not yet recruiting
- Relapsed/Refractory Acute Myeloid Leukemia
- AMG 553
-
Duarte, California
- +2 more
Dec 22, 2021
B7-H3-positive Relapsed/ Refractory Neuroblastoma Trial in Tianjin (T cell injection targeting FLT3 chimeric antigen receptor)
Not yet recruiting
- B7-H3-positive Relapsed/ Refractory Neuroblastoma
- T cell injection targeting FLT3 chimeric antigen receptor
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Nov 1, 2022
Acute Myeloid Leukemia Trial in United States (Quizartinib, Milademetan)
Terminated
- Acute Myeloid Leukemia
-
Los Angeles, California
- +7 more
Mar 14, 2022
Acute Myeloid Leukemia (AML) Trial in Chengdu (SKLB1028, Salvage Chemotherapy)
Recruiting
- Acute Myeloid Leukemia (AML)
- SKLB1028
- Salvage Chemotherapy
-
Chengdu, Sichuan, ChinaWest China hospital of Sichuan University
Nov 1, 2021
Leukemia, Myeloid, Acute Trial in United States (CPX-351, Quizartinib)
Terminated
- Leukemia, Myeloid, Acute
-
Denver, Colorado
- +4 more
May 10, 2022
Patterns and Key Healthcare Resource Use in Acute Myeloid
Completed
- Acute Myeloid Leukemia (AML)
- Treatment patterns among AML patients
- AML-related healthcare resources
-
Charlotte, North CarolinaSermo
Jan 25, 2022
New Cytokine-based Dynamic Stratification Based on FLt3 Ligand
Recruiting
- Acute Myeloid Leukemia
- No intervention
-
Strasbourg, Bas-Rhin, France
- +24 more
Aug 25, 2021
Leukemia, Acute Myeloid (AML) Trial in Worldwide (gilteritinib, LoDAC (Low Dose Cytarabine), Azacitidine)
Active, not recruiting
- Leukemia, Acute Myeloid (AML)
- gilteritinib
- +4 more
-
Birmingham, Alabama
- +125 more
Aug 9, 2022
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation Trial in Worldwide (gilteritinib, LoDAC (Low Dose
Active, not recruiting
- Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
- gilteritinib
- +3 more
-
Beijing, China
- +47 more
Aug 17, 2022
Relapsed or Refractory Acute Myeloid Leukemia (AML) Trial in Suzhou (HYML-122)
Recruiting
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Feb 6, 2022
Response to Immune Checkpoint Blockade in Metastatic Melanoma
Completed
- Melanoma
- F-FDG PET/CT
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
Jul 7, 2022
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large
Completed
- Lymphoma
- +2 more
- FLT-PET/CT
- +2 more
-
Los Angeles, California
- +3 more
May 6, 2021